bullish

Takeda: Guidance Lowered Due to Setbacks in Clinical Trials but Pipeline Development Continues

1k Views27 Oct 2023 11:29
Recent setback in some of Takeda’s clinical trials has led to downward revision of profit guidance. Takeda remains focused on pipeline development and newly launched drugs show strong potential
Boomeranged on Thu, 9 Nov 2023 17:22
As we have highlighted, Takeda continues to make good progress with its development pipeline where the company has received FDA approval for Fruquintinib/Fruzaqla (acquired from Hutchmed) yesterday. At the same time, the company also announced that its Psoriasis drug TAK-279 (acquired from Nimbus Therapeutics) has met primary endpoint in Phase IIb trial and will initiate phase III trials.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x